$NOVN

Novan Inc

  • NASDAQ
  • Health Technology
  • Pharmaceuticals: Major
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$2.55 β–Ό-1.163%

Extented Hours

VOLUME

69,804

DAY RANGE

2.52 - 2.67

52 WEEK

2.24 - 20.74

Join Discuss about NOVN with like-minded investors

profile
@dros #droscrew
recently

+Initiations 10/20: $AGL $CANO $CDNS $CMAX $CMCT $CMPX $CWAN $CYCN $DDMX $EGP $FR $IMCR $INDI $INDT $JSPR $MTLS $NOVN $OSH $QSI $QIPT $SNPS

88 Replies 9 πŸ‘ 10 πŸ”₯

profile
@Chano #StockTraders.NET
recently

$NOVN offering?

102 Replies 11 πŸ‘ 14 πŸ”₯

profile
@TraderXx #StockTraders.NET
recently

$NOVN ! need to keep an eye on it

92 Replies 8 πŸ‘ 8 πŸ”₯

profile
@Warhog #StockTraders.NET
recently

$NOVN didn't look so strong given the lower vol compared to Fri

90 Replies 12 πŸ‘ 7 πŸ”₯

profile
@maletone #StockTraders.NET
recently

$novn hugging vwap...can see this going over $20 again

117 Replies 14 πŸ‘ 12 πŸ”₯

profile
@TraderXx #StockTraders.NET
recently

longs working well on $NOVN today

144 Replies 10 πŸ‘ 10 πŸ”₯

profile
@TraderXx #StockTraders.NET
recently

$NOVN : 13,964,765 shares of common stock issuable upon the exercise of outstanding warrants having a weighted average exercise price of $3.43 per share.

118 Replies 8 πŸ‘ 12 πŸ”₯

profile
@TraderXx #StockTraders.NET
recently

Where did you get this number from? > @Valckrie said: NOVN has warrants at 46$ right ?

144 Replies 12 πŸ‘ 8 πŸ”₯

profile
@TraderXx #StockTraders.NET
recently

I might regret selling all of $NOVN

76 Replies 7 πŸ‘ 11 πŸ”₯

VA
@Valckrie #StockTraders.NET
recently

NOVN has warrants at 46$ right ?

62 Replies 13 πŸ‘ 11 πŸ”₯

profile
@TraderXx #StockTraders.NET
recently

$NOVN volume tho.. love it

103 Replies 11 πŸ‘ 8 πŸ”₯

profile
@TraderXx #StockTraders.NET
recently

$NOVN PT raised to 90 from 40 due to successfull Phase 3

101 Replies 13 πŸ‘ 11 πŸ”₯

profile
@TraderXx #StockTraders.NET
recently

$NOVN similar to ydays $MEDS run at the start, and than no volume to be found

120 Replies 15 πŸ‘ 14 πŸ”₯

profile
@viking #StockTraders.NET
recently

Upside: -NOVN +32% (reports positive topline results from pivotal Phase III trial of SB206 in patients with molluscum contagiosum) -PGEN +28% (announces positive topline results from Phase 1b/2a study of AG019 ActoBiotics, a Novel Therapy designed to address the underlying cause of Type 1 Diabetes; primary endpoints were met) -GENE +15% (US Patent Office grants foundational pharmacogenomic patent) -MX +15% (confirms 21% improved rival bid of $35/shr cash unsolicited proposal from Cornucopia Investment Partners) -ZDGE +9.5% (earnings, guidance) -ATC +8.4% (MKS Instruments said to have approached Atotech for acquisition) -ADMP +5.9% (provides update on clinical trial start-up progress for tempol in the treatment of COVID-19) -RFP +5.6% (announces $1/share Special Dividend, and $50M in lumber investments) -PLAY +5.3% (earnings, guidance) -AUTL +5.1% (presents new data on obe-cel in r/r Indolent B cell lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual Congress) -MBIO +5.0% (announced updated interim Phase 1/2 data for MB-106) -TYME +5.0% (comprehensive strategic review identified breast cancer as a priority indication for development, a focus on second-line pancreatic cancer, and continuation of trial in high-risk sarcomas) -LIFE +2.5% (presents poster demonstrating functional selectivity of second Anti-NRP2 Antibody) -OCGN +1.4% (Roth Capital broker downgrade) -AVO +1.3% (earnings, guidance) Downside: -ORPH -52% (application for MIPLYFFA under priority review with FDA, expected Prescription Drug User Fee Act action date of June 17; company not aware for reason for stock volatility) -VRTX -14% (reports primary endpoint achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency but magnitude of treatment effect observed unlikely to translate into substantial clinical benefit) -CVAC -11% (downside momentum) -INCY -4.0% (FDA extendes the New Drug Application review period for ruxolitinib cream for the treatment of atopic dermatitis) -ADC -3.9% (prices 4.0M shares at implied $71.50/shr to raise $286M) -SNOW -3.7% (provides 2029 financial targets) -ELY -3.6% (to join S&P MidCap 400) -LTHM -3.2% (prices 13M shares at $17.50/shr) -AGNC -3.1% (reports tangible net book value) -RCL -2.1% (two guests aboard Celebrity Millennium test positive for COVID during required end-of-cruise testing) -CHWY -1.4% (earnings, guidance)

127 Replies 6 πŸ‘ 15 πŸ”₯

profile
@viking #StockTraders.NET
recently

Upside: -RMED +45% (momentum) -LMNL +44% (momentum following FDA approval for its Biologics License Application for Ryplazim) -USCR +28% (to be acquired by Vulcan Materials for $74.00/shr in cash valued at $1.29B) -QTS +21% (to be acquired by Blackstone at $78.00/shr for a total transaction value of $10B) -BNGO +14% (names Jason Priar as its Chief Commercial Officer) -EVFM +14% (momentum) -MIC +12% (confirms to sell Atlantic Aviation unit for $4.48B in cash and assumed debt and reorganization obligations) -CDXC +11% (ChromaDex and Walmart launch Tru Niagen in 3,800 (from 3K prior) Walmart Stores Across the United States) -GIII +8.1% (earnings, guidance) -BLUE +7.4% (announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and ß-Thalassemia Studies) -VERU +5.0% (announces positive data at ASCO) -BIIB +4.7% (Biogen and Bio-Thera announce positive results from Phase 3 study of BAT1806) -NOVN +2.3% (results from Novan’s Exploratory Studies further demonstrate Antimicrobial Effect of NITRICILβ„’ Platform Technology with NVN4100 in Companion Animal Health) -KKR +1.1% (MIC confirms to sell Atlantic Aviation unit for $4.48B in cash and assumed debt and reorganization obligations) Downside: -MOSY -12% (files to sell 1.8M shares at $7.15/shr for a total value of $13M) -PIXY -7.3% (files to sell up to 10.1M shares for holders) -WERN -2.0% (hearing cut at Goldman Sachs to Sell from Neutral) -MSTR -1.2% (to incur $284.5M impairment loss in Q2 due to fluctuations in Bitcoin; files to sell $400M of Senior secured 2028 notes)

148 Replies 12 πŸ‘ 10 πŸ”₯

profile
@nd #StockTraders.NET
recently

$NOVN LONG @1.02

108 Replies 15 πŸ‘ 14 πŸ”₯

AN
@andres168 #StockTraders.NET
recently

$NOVN news about covid

116 Replies 8 πŸ‘ 12 πŸ”₯

Key Metrics

Market Cap

49.47 M

Beta

1.24

Avg. Volume

92.17 K

Shares Outstanding

19.17 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-11

Next Dividend Date

Company Information

Novan, Inc. is a clinical development-stage biotechnology company focused on leveraging its proprietary nitric oxide (NO) based technology platform, NITRICILβ„’ to generate macromolecular New Chemical Entities (NCEs) to treat multiple indications in dermatology, men's and women's health, infectious diseases and gastroenterology conditions with significant unmet needs. The Company's lead product candidate, SB206, a topical antiviral gel, for the treatment of molluscum contagiosum, is currently being evaluated in the B-SIMPLE4 pivotal Phase 3 clinical study. The Company believes that SB206 as a topical, at-home, caregiver-applied therapy with a rapid treatment benefit, if approved, would address an important patient-care need for the treatment of molluscum.

CEO: Paula Stafford

Website:

HQ: 4105 Hopson Rd Morrisville, 27560-9018 North Carolina

Related News